2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1662 TEAM trial: A multicenter phase II trial targeting epigenetic therapy resistance in r/r AML with a Bortezomib-based salvage therapy

Enise Ceran, MD, Shifaa M. Abdin, PhD2, Ulrike Schäkel, MD3, Lisa-Marie Lanz4, Stefanie Göllner, PhD5, Christoph Röllig, MD6, Martin Bornhaeuser, MD7, Mathias Hänel, MD8, Maxi Wass9, Christine Dierks, MD10, Klaus H Metzeler, MD11, Karsten Spiekermann, MD12, Katharina Götze, MD13, Christoph Schliemann, MD14, Kerstin Schaefer-Eckart, MD15, Martin Kaufmann, MD16, Walter Aulitzky, MD17, Björn Steffen18, Hubert Serve, MD19, Stefan W. Krause20, Claudia D Baldus, MD21, Utz Krug22, Claudia Wickenhauser23, Marcus Bauer, MD24, Michael Hundemer, MD25, Tim Sauer, MD26, Richard F Schlenk, MD27, Carsten Mueller-Tidow, MD28
1 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
2 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
3 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
4 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany
5 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
6 National Center of Tumor Diseases Dresden, Dresden, Germany, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany
7 National Center of Tumor Diseases Dresden, Dresden, Germany, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany
8 Klinikum Chemnitz, Chemnitz, Germany
9 Klinikum St. Georg, Leipzig, Germany
10 Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
11 University Hospital Leipzig, Leipzig, Germany
12 LMU University Hospital, Munich, Germany
13 University Hospital rechts der Isar, Technical University of Munich (TUM) School of Medicine, Munich, Germany
14 University Hospital Münster, Münster, Germany
15 Klinikum Nürnberg / Paracelsus Medical University, Nuremberg, Germany
16 Robert Bosch Hospital, Stuttgart, Germany
17 Robert Bosch Hospital, Stuttgart, Germany
18 University Hospital Frankfurt, Goethe University, Frankfurt, Germany
19 University Hospital Frankfurt, Goethe University, Frankfurt, Germany
20 Universitätsklinikum Erlangen, Erlangen, Germany
21 University Medical Center Schleswig-Holstein, Kiel, Germany
22 DKMS Collection Center, Cologne, Germany, Klinikum Leverkusen, Leverkusen, Germany
23 Institute of Pathology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
24 Institute of Pathology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
25 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
26 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
27 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
28 Clinical Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany

Introduction: Relapsed or refractory (r/r) acute myeloid leukemia (AML) carries a poor prognosis, and effective salvage options remain limited. We have recently demonstrated that loss of the histone methyltransferase EZH2 induces epigenetic resistance in r/r AML, and that proteasome inhibition with bortezomib can restore EZH2 levels and resensitize leukemic blasts to cytotoxic therapy (Göllner et al., Nat Med 2017). Based on these findings we conducted a clinical trial with a novel bortezomib, gemtuzumab ozogamicin and cytarabine (B-GA) regimen as salvage treatment in adults with r/r AML.

Methods: In this prospective, open-label, multicenter phase II study (NCT04173585), adults with r/r AML received a 4-day B-GA regimen consisting of bortezomib 1.3 mg/m² subcutaneously on days 1 and 3 (administered 3 hours before cytarabine), cytarabine 1 g/m² intravenously over 3 hours twice daily on days 1-3, and gemtuzumab ozogamicin 3 mg/m² intravenously over 2 hours on days 1 and 4.The primary endpoint was complete remission (CR) or CR with incomplete hematologic recovery (CRi) rate, defined as the proportion of patients achieving CR or CRi according to ELN 2017 criteria. Key secondary endpoints included event-free survival (EFS), relapse-free survival (RFS), overall survival (OS), and minimal residual disease (MRD). MRD was evaluated by a seven-tube, 8-color multiparameter flow cytometry using a leukemia-associated immunophenotype (LAIP) approach. The MRD cut-off was 1×10-4 and the limit of detection was 3×10-5. Overall response rate (ORR) was evaluated using a matched threshold crossing (MTC) design, an adaptation of Simon's optimal two-stage design that matches patients to historical controls (relapsed and refractory cohorts; Schlenk et al., Leukemia 2017 and Wattad et al., Leukemia 2017) on molecular and clinical prognostic markers. The design tested an unfavorable response rate (p0) of ≤0.30 against a target rate (p1) of ≥0.50. Time-to-event endpoints were estimated by Kaplan-Meier methods.

Results: Between January 2020 and February 2023, 51 patients were treated across 11 centers within the AMLCG and SAL networks in Germany. The median age was 62 years (range, 28-75), and 70.6% were male. Overall, 84% of patients had relapsed disease and 16% had refractory disease. Prior allogeneic hematopoietic stem cell transplantation had been performed in 23 of 51 patients (45.1%). In the relapsed cohort (n=43), cytogenetics were evaluable in 42 patients. Adverse risk was present in 19 (45%) and favorable risk in 2 (5%). FLT3 and biallelic CEBPA mutations were each present in 7/43 (16%). In the refractory cohort (n=8), FLT3 mutations were present in 3/8, and no adverse-risk cytogenetics were observed. ORR was 33.3% (17/51; 95% CI, 20.8–47.9), with 10 patients (19.6%) achieving CR and 7 (13.7%) achieving CRi. The predefined threshold of the MTC design was not met: 17 responses remained below the limit of 24 required to reject the null hypothesis. Among the 17 responders, median RFS was 10.8 months. Median OS from trial entry was 14.5 months. MRD conversion from positive to negative was observed in 12/47 evaluable patients (25.5%) by the end of study; 33/47 (70.2%) remained MRD-positive, and 2 patients (4.3%) had missing MRD status. Toxicity was consistent with expectations for this setting. All patients experienced at least one AE (all causalities), most commonly pyrexia (52.9%), febrile neutropenia (43.1%), and nausea (31.4%). Treatment-related AEs occurred in 45 patients (88.2%). SAEs occurred in 7 patients (13.7%), including 2 patients (3.9%) with a treatment-related SAE, both reported as SUSARs (cardiac failure, resolved; and fatal pneumonia). Grade ≥3 AEs occurred in 39 patients (76.5%), and 4 patients (7.8%) had a fatal AE.

Conclusion: In this phase II trial in a high-risk r/r AML population, B-GA produced an ORR similar to the historical reference rate and was associated with encouraging overall survival. MRD negativity at the end of study indicated that responses were deep in a subset of the cohort. These findings suggest that B-GA is not suitable as a treatment option for an unselected r/r AML population; rather, characteristics of patients achieving deep remissions may help refine patient selection in future studies.

Enise Ceran, MD: No relevant conflicts of interest to declare.